<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103283</url>
  </required_header>
  <id_info>
    <org_study_id>DME01RV</org_study_id>
    <nct_id>NCT02103283</nct_id>
  </id_info>
  <brief_title>A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)</brief_title>
  <official_title>Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>River Vision Development Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>River Vision Development Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular
      Edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Open-Label Safety and Pharmacodynamic Study of RV 001, an Insulin-Like Growth
      Factor-1 Receptor (IGF-1) Antagonist, Given By IV Infusion in Patients with Diabetic Macular
      Edema (DME).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of RV001in subjects with Diabetic Macular Edema</measure>
    <time_frame>Change from Baseline to Week 9</time_frame>
    <description>Number of subjects with adverse events, serious adverse events and early discontinuations due to adverse events. Number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of RV001in subjects with Diabetic Macular Edema</measure>
    <time_frame>Change from Baseline to Week 9</time_frame>
    <description>Pharmacodynamic measure includes change in Optical Coherence Tomography, Fluorescein Angiography and Stereoscopic color funds photos findings.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Teprotumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teprotumumab</intervention_name>
    <description>Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions</description>
    <arm_group_label>Teprotumumab</arm_group_label>
    <other_name>RV 001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes mellitus with Hemoglobin A1c &lt;8.5%

          -  IGF 1 in serum &gt; 106 ng/mL

          -  Women of child-bearing potential must have negative pregnancy test and be willing and
             able to use two different methods of contraception, one of which must be oral
             contraceptive or depot formulation. Males must be surgically sterile or agree to use
             barrier contraception

          -  Clinically significant DME of less than 12 months duration

          -  Non-proliferative diabetic retinopathy of moderate severity

          -  Best corrected electronic ETDRS letter score &lt; 78 and &gt; 24

        Exclusion Criteria:

          -  Unstable-uncontrolled diabetes as demonstrated by a change in diabetes medication
             greater than 15% in the previous 60 days.

          -  Significant renal disease, myocardial infarction, stroke, transient ischemic attack,
             acute congestive heart failure

          -  Blood pressure &gt; 180/110

          -  Anti-vascular endothelial growth factor (VEGF) treatment within two months prior to
             enrollment

          -  History of pan retinal photocoagulation within four months prior to enrollment

          -  History of ocular surgery within four months prior to enrollment

          -  History of systemic treatment with corticosteroids within 3 months prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Boyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Vitreous Associates Beverley Hills, California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David S Boyer</name>
      <address>
        <city>Beverley Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David A Eichenbaum, MD</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diana Do, MD</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

